ABBVIE
A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis
- Conditions
- Dermatitis
- Interventions
- Biological: RisankizumabBiological: Placebo
- First Posted Date
- 2018-10-15
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 172
- Registration Number
- NCT03706040
- Locations
- 🇨🇦
Beacon Dermatology Inc /ID# 213003, Calgary, Alberta, Canada
🇦🇺Fremantle Dermatology /ID# 204784, Fremantle, Western Australia, Australia
🇺🇸Center for Dermatology Clinical Research /ID# 204950, Fremont, California, United States
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy
- Conditions
- Ulcerative Colitis (UC)
- Interventions
- First Posted Date
- 2018-10-04
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 42
- Registration Number
- NCT03695185
- Locations
- 🇺🇸
Banner University Medical Cent /ID# 208392, Tucson, Arizona, United States
🇺🇸Meridian Investigator Network /ID# 218568, Lakewood, California, United States
🇺🇸The University of Chicago DCAM /ID# 207086, Chicago, Illinois, United States
A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)
- Conditions
- Central Precocious Puberty (CPP)
- Interventions
- First Posted Date
- 2018-10-04
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 45
- Registration Number
- NCT03695237
- Locations
- 🇺🇸
Rady Children's Hospital San Diego /ID# 202491, San Diego, California, United States
🇺🇸Van Meter Pediatric Endocrinology /ID# 201688, Atlanta, Georgia, United States
🇺🇸Rocky Mountain Diabetes and Osteoporosis Center /ID# 209878, Idaho Falls, Idaho, United States
A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- First Posted Date
- 2018-09-25
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 242
- Registration Number
- NCT03682705
- Locations
- 🇺🇸
Tekton Research, Inc. /ID# 167475, Austin, Texas, United States
🇺🇸Institute of Arthritis Researc /ID# 170694, Idaho Falls, Idaho, United States
🇺🇸DM Clinical Research /ID# 167444, Tomball, Texas, United States
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
- Conditions
- Psoriatic Arthritis
- Interventions
- Biological: PlaceboBiological: Risankizumab
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 964
- Registration Number
- NCT03675308
- Locations
- 🇮🇹
Duplicate_Azienda Ospedaliero-Universitaria Policlinico di Modena /ID# 207799, Modena, Emilia-Romagna, Italy
🇺🇸Medvin Clinical Research /ID# 211127, Whittier, California, United States
🇺🇸June DO, PC /ID# 208915, Lansing, Michigan, United States
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
- Conditions
- Psoriatic Arthritis (PsA)
- Interventions
- Biological: PlaceboBiological: Risankizumab
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 444
- Registration Number
- NCT03671148
- Locations
- 🇺🇸
Arthritis and Rheumatology /ID# 169438, Atlanta, Georgia, United States
🇺🇸Clinic of Robert Hozman/Clinical Investigation Specialists /ID# 166681, Skokie, Illinois, United States
🇺🇸DM Clinical Research /ID# 208350, Tomball, Texas, United States
A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 272
- Registration Number
- NCT03661138
- Locations
- 🇯🇵
Fukuyama City Hospital /ID# 206761, Fukuyama-shi, Hiroshima, Japan
🇯🇵Nagoya City University Hospital /ID# 207566, Nagoya shi, Aichi, Japan
🇯🇵Central Clinic /ID# 206558, Nagoya-shi, Aichi, Japan
A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 272
- Registration Number
- NCT03659669
- Locations
- 🇮🇱
Tel Aviv Sourasky Medical Center /ID# 206962, Tel Aviv-Yafo, Tel-Aviv, Israel
🇮🇱Rabin Medical Center /ID# 206961, Petakh Tikva, Israel
🇮🇱Hadassah /ID# 207898, Jerusalem, Israel
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 522
- Registration Number
- NCT03653026
- Locations
- 🇺🇸
TLC Clinical Research Inc /ID# 216831, Los Angeles, California, United States
🇺🇸Universal Axon Clinical Research /ID# 213462, Doral, Florida, United States
🇺🇸Gastrointestinal Biosciences Clinical Trials, LLC /ID# 205314, Los Angeles, California, United States
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 32
- Registration Number
- NCT03646604
- Locations
- 🇺🇸
Children's Hospital Los Angeles /ID# 206042, Los Angeles, California, United States
🇺🇸Cincinnati Children's Hospital /ID# 207071, Cincinnati, Ohio, United States
🇺🇸Beach Pediatrics /ID# 207834, Huntington Beach, California, United States